2. European Society of Cardiology. 2020 guidelines for of atrial fibrillation. ESC clinical practice guidelines. URL: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management (date of access – 01.09.2023).

3. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984; 24(4): 129–47. https://dx.doi.org/10.1002/j.1552-4604.1984.tb01822.x.

4. Официальные инструкции по применению лекарственных препаратов с МНН пропафенон. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/ (дата обращения – 01.09.2023).

5. RxList. Propafenone.URL: https://www.rxlist.com/consumer_propafenone_rythmol_rythmol_sr/drugs-condition.htm (date of access – 01.09.2023).

6. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9(9): CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub5.

7. Lafuente-Lafuente C., Longas-Tejero M., Bergmann J., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012; (5): CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub3.

8. Официальные инструкции по применению лекарственных препаратов с МНН соталол. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/ (дата обращения – 01.09.2023).

9. RxList. Sotalol. URL: https://www.rxlist.com/consumer_sotalol_betapace/drugs-condition.htm (date of access – 01.09.2023).

10. Dewland T.A., Vittinghoff E., Mandyam M.C. et al. Atrial ectopy as a predictor of incident atrial fibrillation: A cohort study. Ann Intern Med. 2013; 159(11): 721–28. https://dx.doi.org/10.7326/0003-4819-159-11-201312030-00004.

11. Gladstone D.J., Dorian P., Spring M. et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: Results from the EMBRACE trial. Stroke. 2015; 46(4): 936–41. https://dx.doi.org/10.1161/STROKEAHA.115.008714.

12. Deyell M.W., Park K.M., Han Y. et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012; 9(9): 1465–72. https://dx.doi.org/10.1016/j.hrthm.2012.05.019.

13. Priori S.G., Blomstrom-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015; 36(41): 2793–867.https://dx.doi.org/10.1093/eurheartj/ehv316.

14. Клинические рекомендации. Желудочковые аритмии. Минздрав России, ФГБУ «ННПЦССХ им. А.Н. Бакулева» Минздрава России, Центр хирургической и интервенционной аритмологии. 2017 г. Доступ: https://racvs.ru/clinic/files/2017/Ventricular-Arrhythmias.pdf (дата обращения – 01.09.2023).

15. Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М. с соавт. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(7): 128–189.

16. Saikawa T., Nakagawa M., Takahashi N. et al. The effect of propafenone on premature ventricular contractions. Jpn Heart J. 2011; 42(6): 701–11. https://dx.doi.org/10.1536/jhj.42.701.

17. Brugada J., Katritsis D.G., Arbelo E. et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41(5): 655–720. https://dx.doi.org/10.1093/eurheartj/ehz467.

18. Клинические рекомендации. Наджелудочковые тахикардии. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Ассоциация сердечно-сосудистых хирургов России, общероссийская общественная организация «Российское кардиологическое общество». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 619. Доступ: https://cr.minzdrav.gov.ru/schema/619_2 (дата обращения – 01.08.2023).

19. Caldeira D., David C., Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012; 105(4): 226–38.https://dx.doi.org/10.1016/j.acvd.2011.11.005.

20. Carlsson J., Miketic S., Windeler J. et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41(10): 1690–96.https://dx.doi.org/10.1016/s0735-1097(03)00332-2.

21. Hohnloser S., Kuck K., Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000; 356(9244): 1789–94. https://dx.doi.org/10.1016/s0140-6736(00)03230-x.

22. Karamichalakis N., Letsas K., Vlachos K. et al. Managing atrial fibrillation in the very elderly patient: Challenges and solutions. Vasc Health Risk Manag. 2015; 11: 555–62. https://dx.doi.org/10.2147/VHRM.S83664.

23. Alboni P., Botto G.L., Baldi N. et al. Outpation treatment of recent-onset atrial fibrillation with the «pill in pocket» approach. N Engl J Med. 2004; 351(23): 2384–91. https://dx.doi.org/10.1056/NEJMoa041233.

24.

25. Azpitarte J., Alvarez M., Baun O. et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997; 18(10): 1649–54.https://dx.doi.org/10.1093/oxfordjournals.eurheartj.a015146.

26. Boriani G., Capucci A., Lenzi T. et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest. 1995; 108(2): 355–58. https://dx.doi.org/10.1378/chest.108.2.355.

27. Boriani G., Biffi M., Capucci A. et al. Oral loading with propafenone: A placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol. 1998; 21(11Pt2): 2465–69.https://dx.doi.org/10.1111/j.1540-8159.1998.tb01202.x.

28. Blanc J., Voinov C., Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol. 1999; 84(9): 1029–32. https://dx.doi.org/10.1016/s0002-9149(99)00493-2.

29. Botto G., Capucci A., Bonini W. at al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: Comparison of two regimens. Int J Cardiol. 1997; 58(1): 55–61. https://dx.doi.org/10.1016/s0167-5273(96)02841-0.

30. Capucci A., Villiani G., Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm:a prospective parallel placebo – controlled multicentred study. Int J Cardiol. 1999; 68(2): 187–96.https://dx.doi.org/10.1016/s0167-5273(98)00363-5.

31. Deneer V., Borgh M., Kingma J. et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci. 2004; 26(2): 66–78. https://dx.doi.org/10.1023/b:phar.0000018593.02291.c0.

32. Fresco C., Proclemer A., Pavan A. et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996; 19(5): 409–12. https://dx.doi.org/10.1002/clc.4960190515.

33. Khan I. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37(2): 542–47. https://dx.doi.org/10.1016/s0735-1097(00)01116-5.

34. Martignani C., Diemberger I., Ziacchi M. et al. Oral loading of propafenone: Restoring its role before restoring rhythm. Europace. 2017; 19(11): 1903. https://dx.doi.org/10.1093/europace/euw264.

35. Meinertz T., Lip G., Lombardi F. et al.; ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial

36. Porterfield J., Porterfield L. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol. 1989; 63(1): 114–16. https://dx.doi.org/10.1016/0002-9149(89)91091-6.

37.

38. Лукьянова И.Ю., Кузнецов А.В., Комарницкий В.М., Козырева А.Г. Изучение эффективности и безопасности препаратов для медикаментозной кардиоверсии у больных с пароксизмальной формой фибрилляции предсердий на догоспитальном этапе. Скорая медицинская помощь. 2017; 18(4): 43–47.

39. Фомина И.Г., Тарзиманова А.И., Вертлужский А.В. с соавт. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации (часть II). Кардиоваскулярная терапия и профилактика. 2005; 4(5): 62–65.

40. Antonelli D., Freedberg N.A., Feldman A. et al. Intravenous propafenone for conversion of atrial fibrillation in the emergency room. Harefuah. 2004; 143(7): 471–74, 551, 552 (In Hebrew)].

41.

42. Capucci A., Boriani G. Intravenous administration of propafenone. J Am Coll Cardiol. 1992; 19(6): 1368–69.https://dx.doi.org/10.1016/0735-1097(92)90350-v.

43.

44. Goy J., Metrailler J., Humair L., de Torrente A. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J. 1991; 122(6): 1788–90. https://dx.doi.org/10.1016/0002-8703(91)90306-3.

45. Haefeli E.W., Vozeh S., Ha H.R., Follath F. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.Clin Pharmacol Ther. 1990; 48(3): 245–54. https://dx.doi.org/10.1038/clpt.1990.146.

46. Liguori A., di Ieso N., D’Armiento F. et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol. 1992; 14(4): 229–32.

47. Madonia S., De Simone M., Brai G. et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: A randomized trial. Ital Heart J. 2000; 1(7): 475–79.

48. Margheri M., Fradella G., Maioli M. et al. Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation. G Ital Cardiol. 1992; 22(3): 257–65.

49. Velazquez Rodriguez E., Cancino Rodriguez C., Arias Estrada S. et al. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex. 2000; 70(2): 160–66.

50. Zadura M., Grossmann G., Modrzewska A. et al. Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation. Pol Merkur Lekarski. 2001; 11(62): 137–39.

51. Тарасов А.В., С.А.Косых С.А., Бушуева Е.В. с соавт. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019; 21(1): 81–86.

52. Antman E.M., Beamer A.D., Cantillon C. et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1988; 12(4): 1005–11. https://dx.doi.org/10.1016/0735-1097(88)90468-8.

53. Fetsch T., Bauer P., Engberding R. et al.; Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J. 2004; 25(16): 1385–94.https://dx.doi.org/10.1016/j.ehj.2004.04.015.

54. Kowey P.R., Yannicelli D., Amsterdam E.; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2004; 94(5): 663–65. https://dx.doi.org/10.1016/j.amjcard.2004.05.038.

55. Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хзонической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010; 15(4): 55–71.

56. Gomes J.A., Ip J., Santoni-Rugiu F. et al. Oral d, l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999; 34(2): 334–39.https://dx.doi.org/10.1016/s0735-1097(99)00213-2.

57. Somberg J., Molnar J. Sotalol versus amiodarone in treatment of atrial fibrillation. J Atr Fibrillation. 2016; 8(5): 1359.https://dx.doi.org/10.4022/jafib.1359.

58. Singh B.N., Singh S.N., Reda D.J. et al.; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18): 1861–72. https://dx.doi.org/10.1056/NEJMoa041705.

59. Waldo A., Camm A., deRuyter H. et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-Sotalol. Lancet. 1996; 348(9019): 7–12.https://dx.doi.org/10.1016/s0140-6736(96)02149-6.

60. Zimetbaum P.J., Josephson M.E. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 353(6): 627–30; author reply 627–30.

61. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18(1): 5–66.

62. Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E. et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007; 99(12): 1721–25.https://dx.doi.org/10.1016/j.amjcard.2007.01.059.

63. Bellandi F., Simonetti I., Leoncini M. et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001; 88(6): 640–45.https://dx.doi.org/10.1016/s0002-9149(01)01806-9.

64. Fetsch T., Bauer P., Engberding R. et al.; Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J. 2004; 25(16): 1385–94.https://dx.doi.org/10.1016/j.ehj.2004.04.015.

65. Kowey P.R., Yannicelli D., Amsterdam E.; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2004; 94(5): 663–65. https://dx.doi.org/10.1016/j.amjcard.2004.05.038.

66. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9(9): CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub5.

67. Lafuente-Lafuente C., Longas-Tejero M., Bergmann J., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012; 5: CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub3.